Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Stock markets ended the week on a high note following reassuring comments from Federal Reserve Chair Jerome Powell.
Apple's stock surges over 6% on Friday, surpassing its 200-day moving average for the first time since Jan 2024. This was driven by a strong quarterly report and a record-breaking share buyback program.
A weaker-than-expected jobs report sparked a widespread market rally in the last session of the week, as traders increased expectations on potential interest rate cuts later this year.
Owens & Minor impresses with Q1 results: adjusted EPS of $0.19, and sales of $2.61B (up 4% Y/Y). Patient Direct revenue reaches $638M (up 5% Y/Y). CEO Edward Pesicka highlights growth strategies and reaffirms 2024 revenue guidance of $10.5-$10.9 billion and adjusted EPS of $1.40-$1.70.
Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer.